QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kielbasa, L. A Articles by Daniel, K. L Search for Related Content PubMed PubMed Citation Articles by Kielbasa, L. A Articles by Daniel, K. L

WOMEN'S HEALTH

Topical Alprostadil Treatment of Female Sexual Arousal Disorder

at time of writing, Ambulatory Care Pharmacy Resident and Instructor, Pharmacy Practice, College of Pharmacy, Nova Southeastern University, Ft. Lauderdale, FL; now, Cardiovascular Pharmacogenomics Fellow, Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL

Karen L Daniel, PharmD CDE

Associate Professor, Pharmacy Practice, and Clinical Coordinator, Pharmacy Services, College of Pharmacy, Nova Southeastern University

Reprints: Dr. Daniel, College of Pharmacy, Nova Southeastern University, 3200 S. University Dr., Ft. Lauderdale, FL 33328-2018, fax 954/262-2278, kdaniel{at}nsu.nova.edu

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of topical alprostadil in the treatment of female sexual arousal disorder (FSAD).

DATA SOURCES: A literature search was conducted using MEDLINE (1966-May 2006), EMBASE, and International Pharmaceutical Abstracts with the search terms alprostadil, female, and sexual dysfunction/drug therapy.

STUDY SELECTION AND DATA EXTRACTION: All published and unpublished clinical trials and abstracts involving the efficacy and safety of topical alprostadil use in women were reviewed. Data on file with the manufacturer were also included.

DATA SYNTHESIS: Topical alprostadil is a vasodilatory agent under development for the treatment of FSAD. In-clinic application of alprostadil increases genital vasocongestion, vaginal erythema, transudates, and some patient-assessed indices of sexual arousal; however, these effects have not been consistently superior to placebo. Three of 4 trials investigating at-home use of topical alprostadil have demonstrated improvements in achievement of satisfactory levels of sexual arousal and successful sexual encounters in patients with FSAD. Adverse events appear to be mild and localized and consist of burning and itching at the application site.

CONCLUSIONS: Two formulations of topical alprostadil are in Phase II clinical trials for the treatment of FSAD. Initial results of clinical trials have demonstrated some beneficial effects on arousal success rates and other subjective measures of sexual arousal; however, these results have been inconsistent and not reproducible in all trials. The results of ongoing clinical studies are needed to further define the role of topical alprostadil in the treatment of FSAD.

Key Words: alprostadil, female sexual arousal disorder, female sexual dysfunction

Published Online, June 6, 2006. www.theannals.com, DOI 10.1345/aph.1G472

This article has been cited by other articles:

				K Wylie and F Malik Review of drug treatment for female sexual dysfunction Int J STD AIDS, October 1, 2009; 20(10): 671 - 674. [Abstract] [Full Text] [PDF]